



**THE RELEVANCE OF THE DIAGNOSIS OF INFECTIOUS  
DISEASES AND THE INTERPRETATION OF MEASURES  
TO IMPROVE DIAGNOSIS**

**Zukhra A. Nuruzova<sup>1</sup>**

**Dilafuz Sh. Gulmurotova<sup>2</sup>**

**Shaxzoda O' Norqulova<sup>3</sup>**

**Mavjuda T. Omonova<sup>4</sup>**

<sup>1</sup>Head of the Department of Microbiology, Virology and  
Immunology,

Professor, DcS, Tashkent State Medical University, Tashkent,  
Uzbekistan. E-mail: voyna\_microbam@mail.ru

<sup>2</sup>Assistant at the Department of Microbiology, virology and  
immunology of Tashkent State Medical University, Tashkent,  
Uzbekistan, E-mail: dilafuzgulmurotova82@gmail.com

<sup>3</sup>Student of Tashkent State Medical University, 1st Faculty of  
General Medicine, Group 217A, Tashkent, Uzbekistan, E-mail:  
norqulovashaxzoda199@gmail.com

<sup>4</sup>Student of Tashkent State Medical University, 2nd Faculty of  
General Medicine, Group 214A, Tashkent, Uzbekistan, E-mail:  
sabrfaqatsabr07@gmail.com

<https://doi.org/10.5281/zenodo.17589089>

**ARTICLE INFO**

Received: 06<sup>th</sup> November 2025

Accepted: 11<sup>th</sup> November 2025

Online: 12<sup>th</sup> November 2025

**KEYWORDS**

*Antibodies, contamination,  
cross-reaction, cytopathic  
impact, acid-fast stain, newly  
emerging infectious diseases,  
Gram stain,  
Immunohistochemistry,  
Reactivation, viral inclusions,  
serology, opportunistic  
infection.*

**ABSTRACT**

*The economy and human civilization are greatly impacted by infectious illnesses, which pose serious threats to world health. Functional probes have shown tremendous promise in recent years as essential biological media for infectious disease research and treatment. Pathogen identification, biological mechanism investigation, and anti-infective medication development are some of their uses in the field of infectious illnesses. An overview of the pathophysiology, classification, and severity of infectious diseases is given in this review. Using common examples, we then looked at the unique features and design approaches of functional probes for infectious illness diagnosis and treatment, providing insight into their logic. We go over the present situation and difficulties surrounding the therapeutic application of functional probes. We also looked into the potential use of these probes in the detection and management of infectious disorders. The purpose of this review is to expand the use of diagnostic probes for infectious diseases in disease treatment by providing new insights into their design. The economy and human civilization are greatly*



IF = 9.2

*impacted by infectious illnesses, which pose serious threats to world health. Functional probes have shown tremendous promise in recent years as essential biological media for infectious disease research and treatment. Pathogen identification, biological mechanism investigation, and anti-infective medication development are some of their uses in the field of infectious illnesses. An overview of the pathophysiology, classification, and severity of infectious diseases is given in this review. Using common examples, we then looked at the unique features and design approaches of functional probes for infectious illness diagnosis and treatment, providing insight into their logic. We go over the present situation and difficulties surrounding the therapeutic application of functional probes. We also looked into the potential use of these probes in the detection and management of infectious disorders. The purpose of this review is to expand the use of diagnostic probes for infectious diseases in disease treatment by providing new insights into their design.*

**Introduction.** Infectious diseases have historically coexisted with the atrocities of war and the plague of starvation, making them an unsurmountable barrier to human progress and survival. They continue to be a major cause of death and disability worldwide even in the modern period. Unquestionably, the global burden of infections is being made worse by the constant appearance of new infections and the periodic recurrence of both known and unknown infectious diseases in the modern world. Innovation in the identification and treatment of infectious diseases has become critically important in response to this growing issue. For the study of infectious diseases, functional probes enhanced with particular biomolecular interactions and information-transmission capabilities provide a fresh viewpoint and approach. These probes have a remarkable capacity to recognize pathogen molecular markers [1,2,3]. These probes are essential in many crucial fields because of their remarkable capacity to recognize pathogen molecular markers and infection-related proteins. Above all, they have enormous promise for early diagnosis and illness detection. The sources of infection can be quickly and accurately identified by customizing probes that bind to certain pathogen protein structures or nucleic acids. By expediting the timely isolation of sick individuals, this flexible diagnostic technique successfully stops outbreaks from spreading. Furthermore, functional probes are essential for deciphering the complex biological processes that underlie infectious illnesses. These probes uncover vital links, such as host immune responses and pathogen invasion pathways, by interacting with important molecules. Functional probes hold a significant place in the field of treating infectious



diseases. By using their affinity for and recognition of infections, they enable targeted medicine delivery and intervention. This exact medication design offers a novel strategy for successfully battling infectious diseases. Functional probes offer previously unheard-of chances to advance infectious disease research and control in this age of growing global health risks [4,5,6,7]. By combining these molecular tools with state-of-the-art technologies, we hope to make progress toward long-term global public health objectives and solve current problems. Clinical microbiology is a science of interpretive judgment that is growing more complex rather than less, in contrast to other sections of the diagnostic laboratory. Whether one suspects a prokaryote or a eukaryote as the etiologic agent—both of which are covered in this document—the quality of the specimens received for analysis still determines how results are interpreted, despite the development of laboratory automation and the integration of genomics and proteomics in microbiology. Microbes typically have a special ability to adapt to conditions where host reactions and antibiotics exert pressures that promote their survival [8,9,10,11]. These mutations may or may not be detected by a laboratory device, which might make clinical interpretation difficult. Microbes obviously grow, proliferate, and die incredibly quickly. Analysis results will be tainted and interpretation may be deceptive if any of those things happen during the preanalytical specimen management procedures. The accuracy, significance, and clinical relevance of the microbiology laboratory's data must be trusted by doctors and other advanced practice providers. Anything less falls short of the community's expectations for laboratory care. However, the laboratory needs all microbiology specimens to be carefully chosen, gathered, and transported in order to maximize analysis and interpretation in order to deliver that level of quality. Specimen management cannot be left up to chance because microbiology results interpretation depends solely on the quality of the specimen submitted for analysis. Those who collect specimens for microbiologic analysis must be aware of what the laboratory needs to provide accurate results as well as what the physician needs for patient care, including making sure that specimens arrive at the laboratory for analysis as soon as possible after collection [12,13,14,15].


**The main purpose** of the presented review manuscript is a brief analysis of the relevance of the diagnosis of infectious diseases and measures to improve diagnosis.

**Clinical translation and difficulties.** By specifically targeting particular molecules, functional probes are essential for the quick identification of pathogens and the early diagnosis of infectious diseases. This competence reduces the risk of epidemic spread while simultaneously accelerating prompt treatment. Concurrently, functional probes explore the complexities of infection mechanisms, shedding light on the dynamics of host-pathogen interactions, immune responses, and crucial stages of disease progression. This procedure creates a solid scientific foundation that is necessary for developing successful treatment plans. Moreover, functional probes offer a great deal of promise for treating infectious disorders. Initially focused on detecting indicators of infectious diseases in controlled settings, these probes were intended for extensive integration into the fields of biology and medicine. Functional probes can accomplish very sensitivity pathogen detection and accurate molecular characterisation by taking use of their unique



recognition capabilities and signal augmentation mechanisms [1,3,4,7]. A plethora of in vivo diagnostic and therapeutic functional probes have surfaced as research continues to advance and functional probe designs have become increasingly sophisticated, sparking radical changes in conventional treatment paradigms. Functional probes have shown promise in vivo, but when they move into clinical settings, they encounter a number of obstacles. First, confirming the reliability and effectiveness of these probe-derived results in actual patient situations will require a great deal of clinical research because clinical validation and reproducibility are still difficult jobs. Furthermore, crucial factors in guaranteeing accurate diagnosis and therapy are the probe's specificity and sensitivity [8-12]. Cross-reactivity and false positives are possible, which emphasizes the necessity of ongoing improvement to increase accuracy. Furthermore, discrepancies between several laboratories may arise from the lack of uniform standards and criteria. Establishing consistent operational procedures and quality control systems is so essential. Last but not least, using functional probes raises ethical and legal issues, especially in a therapeutic setting. As a result, it is crucial to guarantee the security and compliance of these probes. Even while functional probes have significantly advanced the clinical adaptation of infectious disease detection and therapy, there are still a number of clinical, ethical, and technical challenges. Functional probes may contribute significantly to improving the accuracy of infectious illness diagnosis, treatment effectiveness, and outbreak control with further study and creative solutions [13-20].

**Molecular Diagnostic Techniques.** Molecular diagnostic techniques are sophisticated biotechnological instruments that provide the quick, sensitive, and targeted identification of infectious illnesses. Traditional diagnostic techniques' slowness and low sensitivity are major drawbacks, particularly for illnesses that need immediate treatment. Molecular techniques, on the other hand, focus on the pathogens' genetic material (DNA and RNA), yielding quicker and more precise results. These methods are essential in clinical settings because they may identify even minute amounts of infectious material and be applied in the early stages of illness. PCR, Real-Time PCR (qPCR), Multiplex PCR, NGS, LAMP, and CRISPR-based diagnostic approaches are currently the most widely used technologies in molecular diagnostics (figure 1). In addition to speeding up the diagnostic procedure, these methods help with treatment planning by offering vital details on the genetic makeup of infectious pathogens [6-11].




**Figure 1. shows how the polymerase chain reaction operates [5].**

**PCR stands for polymerase chain reaction.** One of the mainstays of molecular diagnostics, PCR has revolutionized the diagnosis of infectious diseases. This method, which was created by Kary Mullis in 1983, enables the quick amplification of a particular target DNA segment millions of times, making it possible to identify even minuscule amounts of genetic information. Because of its high sensitivity, PCR is becoming a vital diagnostic technique for infectious illnesses. PCR is now considered the "gold standard" in clinical microbiology labs and is used to identify a variety of microorganisms, such as viruses, bacteria, fungus, and parasites. The basic idea behind PCR is to use primers to amplify a certain area of DNA or RNA in order to detect the pathogen in a lab setting. This method's capacity to identify even minute amounts of harmful DNA or RNA is one of the primary factors contributing to its extensive use in infectious diseases. Particularly in the early stages of viral illnesses like HIV, Hepatitis B (HBV), and Hepatitis C (HCV), PCR yields extremely sensitive and specific results. Similarly, PCR provides quicker and more accurate results than conventional culture techniques for bacterial illnesses such tuberculosis, *Legionella pneumophila*, and *Streptococcus pneumoniae* [14-20]. Advanced PCR variations have significantly improved the diagnosis of infectious illnesses over time. For instance, Real-Time PCR (qPCR) amplifies DNA and simultaneously measures the amount of amplified DNA in real time. Both qualitative and quantitative analysis are made possible by qPCR, which uses a fluorescent signal to track the amplification process and show how much target DNA is being duplicated. This technology is essential for assessing the burden of disease and tracking therapy response. qPCR is a potent method for pathogen detection because of its high sensitivity and specificity. It was the most popular

technique for identifying SARS-CoV-2 during the COVID-19 pandemic. Additionally, qPCR is crucial for detecting co-infections since it can identify several pathogens at once [6-12].

**Isothermal Amplification Mediated by Loops (LAMP).** Nucleic acid identification by amplification techniques has been successfully applied in diagnostic procedures for the precise identification and detection of causative organisms in the management of a number of infectious disorders. The PCR, which multiplies target DNA sequences precisely and rapidly, is the gold standard for nucleic acid-based diagnostic applications [9,10,17].



**Figure 2: Loop-mediated isothermal amplification (LAMP) method workflow.**

In addition to the benefits of PCR, several molecular diagnostic techniques have been developed in recent years. These techniques provide quicker, more affordable, and portable solutions by overcoming some of PCR's drawbacks. LAMP is one such cutting-edge technique. DNA or RNA can be amplified at a steady temperature using LAMP, a quick and sensitive molecular diagnostic method. In contrast to PCR, the LAMP technique operates under isothermal conditions—that is, at a single, constant temperature—and does not require a thermal cycler. LAMP, which typically operates between 60 and 65 °C, produces fast results and is renowned for being simple to use in outdoor settings [1,5,7,8].

**Future Perspectives and Challenges.** *The Future Role of Molecular Diagnostic Methods.* In the future, the integration of artificial intelligence (AI) and machine learning (ML) technologies into the analysis of molecular diagnostic data will make diagnostic processes faster and more accurate. Particularly in the analysis of NGS and metagenomic data, where large amounts of data are generated, AI and ML algorithms can contribute in the following ways: Automation of Data Analysis: AI-assisted analyses improve the accuracy of antibiotic resistance and genetic variations in pathogens, thereby reducing



diagnostic time and minimizing human error. Detection of Resistance Genes and Mutations. This makes it possible to quickly identify the best course of action. The function of machine learning and artificial intelligence. Molecular diagnostic techniques allow clinical laboratories to perform diagnostic procedures more quickly and precisely [5-11]. It is anticipated that cutting-edge technologies like PCR, NGS, and CRISPR will proliferate and become more widely available in the future. Considerable progress is expected in the following areas when these technologies become commonplace in healthcare: Widespread Use of Rapid Diagnostic Tests: The proliferation of rapid diagnostic tests in rural and field settings will be made possible by the creation of affordable, portable molecular diagnostic instruments. This offers a significant benefit, especially in terms of early outbreak detection and managing the spread of infectious illnesses. Applications of customized Medicine: Molecular diagnostic technologies will enable more efficient treatment planning by supporting customized medicine strategies like genetic profiling and the identification of specific disease risks. Applications of customized Medicine: Molecular diagnostic technologies will enable more efficient treatment planning by supporting customized medicine strategies like genetic profiling and the identification of specific disease risks. Additionally, employing locally produced materials when possible, streamlining diagnostic workflows, and developing specialized training programs for medical professionals can all help to promote sustainable integration. These tactics would improve disease surveillance and enable prompt responses to outbreaks by strengthening local public health systems and expanding access to necessary diagnostic instruments. Despite financial limitations, molecular diagnostics can significantly improve healthcare outcomes in low- and middle-income nations through these initiatives [12-16].

**Discussion.** Both human civilization and the economy are greatly impacted by infectious diseases, which pose serious threats to world health. Functional probes have shown great promise as essential biological tools for the study and management of infectious illnesses in recent years. Pathogen identification, biological mechanism research, and the creation of anti-infective medications are some of their uses in the field of infectious illnesses. The severity, categorization, and pathophysiology of infectious diseases are succinctly introduced in this overview. We then looked at the uniqueness and design approaches of functional probes for infectious illness diagnosis and treatment, illuminating their design reasoning with typical cases. We go over the state of the art and difficulties in using functional probes in clinical settings. We also looked into the potential applications of these probes for infectious disease diagnosis and therapy. The purpose of this review is to expand the use of diagnostic probes in the treatment of infectious diseases and to provide new insights into their design. This document, created by experts in both adult and pediatric laboratory and clinical medicine, provides information on which tests are valuable and in which contexts, as well as on tests that add little or no value for diagnostic decisions. The critical nature of the microbiology laboratory in infectious disease diagnosis necessitates a close, positive working relationship between the physician and the microbiologists who provide enormous value to the health care team [1-5]. Bloodstream infections and infections of the cardiovascular system, central



nervous system infections, ocular infections, soft tissue infections of the head and neck, upper respiratory tract infections, lower respiratory tract infections, intraabdominal infections, infections of the gastrointestinal tract, bone and joint infections, urinary tract infections, genital infections, and skin and soft tissue infections. Each section includes an introduction, a synopsis of the main ideas, and comprehensive tables that list suspected agents, the most dependable tests to order, the samples (and volumes) to collect in order of preference, specimen transport devices, procedures, times, and temperatures, and detailed notes on particular test method issues, such as when tests are likely to require a specialized laboratory or have long turnaround times. Additionally, the specimen management requirements for children are taken into consideration. Since many agents and assay options overlap, there is duplication across the tables and sections. The purpose of the publication is to help doctors choose tests that would help them diagnose infectious disorders in their patients [6-11]. Artificial intelligence and machine learning will probably be integrated into molecular diagnostics in the future to automate the interpretation of complicated datasets produced by technologies like metagenomics and NGS. This method could help identify resistance genes and new infections while also greatly improving the speed and accuracy of diagnostic procedures. Furthermore, the creation of suitable regulatory frameworks is necessary to address ethical issues pertaining to the privacy of genetic data and the use of sensitive information. As CRISPR-based diagnostics develop, they have the potential to further transform the industry by offering quick, field-deployable testing for newly developing infectious diseases and tailored medical solutions. When taken as a whole, these developments promise better patient outcomes, more efficient disease control, and the ability to revolutionize international health practices [12-17].

**Conclusions.** There is great potential for using functional probes to detect infectious illnesses. We expect the development of functional probes with improved multiplexing capabilities, higher sensitivity, and more sophisticated imaging modalities as technology improves. With the ability to accurately tailor treatments to each individual's own infection profile, these advanced probes have the potential to support a paradigm shift toward individualized medical interventions. Furthermore, combining functional probes with other state-of-the-art therapeutic and diagnostic techniques may completely change how infectious diseases are treated. For instance, there are numerous benefits to integrating intelligent terminals with functional probes. First, real-time biometric data, vital signs, symptoms, and other information can be gathered by the intelligent terminal and sent to the cloud system for prompt analysis and diagnosis.

Second, cloud systems can sort through enormous patient data sets using artificial intelligence and big data to offer tailored diagnoses and treatment suggestions. Furthermore, cloud systems can incorporate worldwide infection data, utilizing predictive modeling and data analytics for epidemic prevention and surveillance. In conclusion, functional probes have enormous and broad promise in the field of infectious illnesses. Their uses include the creation of new medicinal drugs, accurate pathogen detection, and the clarification of complex systems. Even if there are still many obstacles to overcome, a steadfast commitment to continuous research and creative advancements



will surely open the door for smooth integration into clinical practice. In the end, this integration looks to be helpful in a new era of precise diagnosis and focused treatment approaches for a variety of infectious diseases.

## References:

1. R. E. Baker, A. S. Mahmud, I. F. Miller, M. Rajeev, F. Rasambainarivo, B. L. Rice, S. Takahashi, A. J. Tatem, C. E. Wagner, L.-F. Wang, A. Wesolowski, C. J. E. Metcalf, *Nat. Rev. Microbiol.* 2021, 20, 193.
2. Schmidt TE, Vieceli T, Damasceno LS, Kimuda S, Pasqualotto AC, Bahr NC. Evolving Epidemiology, Improving Diagnostic Tests and Their Importance for the Correct Diagnosis of Histoplasmosis. *Journal of Fungi.* 2025; 11(3):196. <https://doi.org/10.3390/jof11030196>
3. <https://www.idsociety.org/practice-guideline/laboratory-diagnosis-of-infectious-diseases/> Skjøt-Arkil H, Heltborg A, Lorentzen MH, et al Improved diagnostics of infectious diseases in emergency departments: a protocol of a multifaceted multicentre diagnostic study *BMJ Open* 2021;11:e049606. doi: 10.1136/bmjopen-2021-049606
4. J Michael Miller, Matthew J Binnicker, Sheldon Campbell, et al., A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 Update by the Infectious Diseases Society of America and the American Society for Microbiology, *Clinical Infectious Diseases*, Volume 67, Issue 6, 15 September 2018, Pages e1–e94, <https://doi.org/10.1093/cid/ciy381>
5. Alsharksi AN, Sirekbasan S, Gürkök-Tan T, Mustapha A. From Tradition to Innovation: Diverse Molecular Techniques in the Fight Against Infectious Diseases. *Diagnostics.* 2024; 14(24):2876. <https://doi.org/10.3390/diagnostics14242876>
6. Kadja, T.; Liu, C.; Sun, Y.; Chodavarapu, V.P. Low-Cost, Real-Time Polymerase Chain Reaction System for Point-of-Care Medical Diagnosis. *Sensors* 2022, 22, 2320.
7. Kostyusheva, A.; Brezgin, S.; Babin, Y.; Vasilyeva, I.; Glebe, D.; Kostyushev, D.; Chulanov, V. CRISPR-Cas systems for diagnosing infectious diseases. *Methods* 2022, 203, 431–446.
8. Lamb, L.E.; Bartolone, S.N.; Ward, E.; Chancellor, M.B. Rapid detection of novel coronavirus (COVID-19) by reverse transcription-loop-mediated isothermal amplification. *PLoS ONE* 2020, 15, e0234682.
9. Corman, V.M.; Landt, O.; Kaiser, M.; Molenkamp, R.; Meijer, A.; Chu, D.K.; Bleicker, T.; Brünink, S.; Schneider, J.; Schmidt, M.L.; et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Euro Surveill.* 2020, 25, 2000045.
10. Dramé, M.; Tabue Tegu, M.; Proye, E.; Hequet, F.; Hentzien, M.; Kanagaratnam, L.; Godaert, L. Should RT-PCR be considered a gold standard in the diagnosis of COVID-19? *J. Med. Virol.* 2020, 92, 2312–2313.
11. Binnie, A.; Fernandes, E.; Almeida-Lousada, H.; de Mello, R.A.; Castelo-Branco, P. CRISPR-based strategies in infectious disease diagnosis and therapy. *Infection* 2021, 49, 377–385.
12. Sebastião, C.S.; Pingarilho, M.; Bathy, J.; Bonfim, E.; Toancha, K.; Miranda, M.N.S.; Martins, M.R.O.; Gomes, P.; Lázaro, L.; Pina-Araujo, I.; et al. MARVEL-minimising the



emergence and dissemination of HIV-1 drug resistance in Portuguese-speaking African Countries (PALOP): Low-cost portable NGS platform for HIV-1 surveillance in Africa. *BMC Infect. Dis.* 2024, 24, 884.

13. Schmitz, J.E.; Stratton, C.W.; Persing, D.H.; Tang, Y.W. Forty Years of Molecular Diagnostics for Infectious Diseases. *J. Clin. Microbiol.* 2022, 60, e0244621.

14. Schoonbroodt, S.; Ichanté, J.L.; Boffé, S.; Devos, N.; Devaster, J.M.; Taddei, L.; Rondini, S.; Arora, A.K.; Pascal, T.; Malvaux, L. Real-time PCR has advantages over culture-based methods in identifying major airway bacterial pathogens in chronic obstructive pulmonary disease: Results from three clinical studies in Europe and North America. *Front. Microbiol.* 2023, 13, 1098133.

15. Ahmadzadeh, M.; Vahidi, H.; Mahboubi, A.; Hajifathaliha, F.; Nematollahi, L.; Mohit, E. Different Respiratory Samples for COVID-19 Detection by Standard and Direct Quantitative RT-PCR: A Literature Review. *Iran J. Pharm. Res.* 2021, 20, 285–299.

16. Freitas, V.L.T.; Novaes, C.T.G.; Sartori, A.M.C.; Carvalho, N.B.; Silva, S.C.V.D.; Nakanishi, É.S.; Salvador, F.; Castro, C.N.; Bezerra, R.C.; Westphalen, E.V.N.; et al. Quantitative PCR as a marker for preemptive therapy and its role in therapeutic control in *Trypanosoma cruzi*/HIV coinfection. *PLoS Negl. Trop. Dis.* 2024, 18, e0011961.

17. Freitas, V.L.T.; Novaes, C.T.G.; Sartori, A.M.C.; Carvalho, N.B.; Silva, S.C.V.D.; Nakanishi, É.S.; Salvador, F.; Castro, C.N.; Bezerra, R.C.; Westphalen, E.V.N.; et al. Quantitative PCR as a marker for preemptive therapy and its role in therapeutic control in *Trypanosoma cruzi*/HIV coinfection. *PLoS Negl. Trop. Dis.* 2024, 18, e0011961.

18. Sule, W.F.; Oluwayelu, D.O. Real-time RT-PCR for COVID-19 diagnosis: Challenges and prospects. *Pan Afr. Med. J.* 2020, 35, 121.

19. van Kasteren, P.B.; van der Veer, B.; van den Brink, S.; Wijsman, L.; de Jonge, J.; van den Brandt, A.; Molenkamp, R.; Reusken, C.B.E.M.; Meijer, A. Comparison of seven commercial RT-PCR diagnostic kits for COVID-19. *J. Clin. Virol.* 2020, 128, 104412.

20. Kay, A.; Vasiliu, A.; Carratala-Castro, L.; Mtafya, B.; Mendez Reyes, J.E.; Maphalala, N.; Munguambe, S.; Mulengwa, D.; Ness, T.; Saavedra, B.; et al. Stool4TB Global Partnership. Performance of a stool-based quantitative PCR assay for the diagnosis of tuberculosis in adolescents and adults: A multinational, prospective diagnostic accuracy study. *Lancet Microbe* 2024, 5, e433–e441.